Opioid

Five things for pharma marketers to know: Monday, September 19, 2016

Five things for pharma marketers to know: Monday, September 19, 2016

By

Some U.S. hospitals still haven't received Valeant discounts; U.N. General Assembly will discuss antibiotic resistance; AstraZeneca diabetes drugs lowered blood sugar in study

The FDA warns drugmakers over promotion of experimental opioid

The FDA warns drugmakers over promotion of experimental opioid

By

The OPDP sent its second untitled letter this week, this time to Durect and Pain Therapeutics over the presentation of Remoxy ER.

Five things for pharma marketers to know: Tuesday, August 23, 2016

Five things for pharma marketers to know: Tuesday, August 23, 2016

By

Grassley blasts Mylan over EpiPen price increases; Portola Pharmaceuticals receives CRL letter for reversal agent; the FDA approves Pfizer's opioid

Five things for pharma marketers to know: Tuesday, August 16, 2016

Five things for pharma marketers to know: Tuesday, August 16, 2016

By

OncoGenex's prostate cancer drug fails in clinical trial; Aetna to exit exchanges in 11 states; pregnant women taking acetaminophen have higher risks for their children

Five things for pharma marketers to know: Tuesday, August 2, 2016

Five things for pharma marketers to know: Tuesday, August 2, 2016

By

IBM develops chip to detect early stages of cancer; Theranos plans to develop a "minilab;" Aetna and Humana to sell $117 million in assets

Five things for pharma marketers to know: Wednesday, July 6, 2016

Five things for pharma marketers to know: Wednesday, July 6, 2016

By

Pfizer to disclose addiction risk in promo materials for opioids; Medivation considers an acquisition; Almirall expresses interest in buying Valeant drugs

Teva targets opioid abuse with the absurd

Teva targets opioid abuse with the absurd

By

The drugmaker launched a three-part video series that uses humor to address prescription drug abuse.

Purdue debuts opioid-abuse resource

Purdue debuts opioid-abuse resource

By

Purdue Pharma launched a new resource around the abuse-deterrent properties of some of its painkillers.

Five things for pharma marketers to know: Monday, August 17

Five things for pharma marketers to know: Monday, August 17

By

Court blocks generic competition for Opana ER until 2023; lawmakers question Valeant drug price hikes; Roche's immuno-oncology drug meets primary endpoint in mid-stage trial

Five things for pharma marketers to know: Tuesday, June 9

Five things for pharma marketers to know: Tuesday, June 9

By

Study shows Merck's Januvia does not increase heart risks; a former Genentech exec launches a behavioral health business; lawmakers want black-box warnings on more opioids

Five things for pharma marketers to know: Monday, May 18

Five things for pharma marketers to know: Monday, May 18

By

Endo agrees to buy Par Pharmaceuticals for $8 billion; AstraZeneca deepens commitment to biologics; FDA cautions that certain diabetes drugs could lead to serious condition

Five things for pharma marketers to know: Friday, May 8

Five things for pharma marketers to know: Friday, May 8

By

Amarin sues FDA over off-label discussions; spike in HCV infections in US blamed on Endo opioid; Pfizer settles gambling, eating and sex addiction lawsuit

Five things for pharma marketers to know: Wednesday, April 1

Five things for pharma marketers to know: Wednesday, April 1

By

Takeda proposes $2.2-billion settlement to resolve Actos suits; Public Citizen says diabetes drugs are unlawfully promoted; PAIN study says 20% to 30% of opioid drugs are misused

Opioid deterrence may work, labeling rules are coming

Opioid deterrence may work, labeling rules are coming

By

A painkiller manufacturer said abuse-resistant formula lessens abuse, just as the FDA comes under pressure to finalize labeling guidance.

Five things for pharma marketers to know: Wednesday, March 18

Five things for pharma marketers to know: Wednesday, March 18

By

GlaxoSmithKline respiratory drug's safety profile will be evaluated by FDA advisory panel; Actavis axes 400 New York jobs; physician testifies that he falsified Diovan clinical trial data

CDC finds patients using more potent opioids

The survey shows the use of stronger-than-morphine painkillers has jumped.

Five things for pharma marketers to know: Tuesday, February 17

Five things for pharma marketers to know: Tuesday, February 17

By

Bayer exec may be Sanofi's new CEO, GSK gets a new North American Pharma lead, and Pfizer sends painkiller ALO-02 to the FDA.

Purdue's new Rx opioid hits market

Purdue's new Rx opioid hits market

By

Hysingla ER is ready for the marketplace, just two months after FDA approval.

Rx painkillers increase risk of birth defects: CDC

The CDC and March of Dimes Foundation are asking prescribers to discuss safer alternatives than opioid painkillers for women who may become pregnant.

Five things for pharma marketers to know: Thursday, January 15

Five things for pharma marketers to know: Thursday, January 15

By

Google teams up with PwC for DOD EHR project bid; FDA approves first weight-loss device since 2007; research says opioid abuse may be on the decline.

Rx-opioid related deaths fall for the first time in 13 years

Rx-opioid related deaths fall for the first time in 13 years

By

The bad news: heroin-related deaths inched upwards.

FDA tempers opioid approval impact

FDA tempers opioid approval impact

By

The Center for Drug Evaluation and Research's director says there is a need for new opioids and cuts off dosing comparisons between extended-release and immediate-release opioids.

Vancouver tests prescription heroin

The north-of-the-border solution comes amid climbing heroin abuse in the US.

FDA approves abuse-deterrent Hysingla ER

The first approved hydrocodone formulated to discourage misuse raises a challenge to controversial Zohydro.

Unsealed court documents shed light on opioid marketing

Drug makers favor big spending on speakers' events and doctor outreach.

American Academy of Neurology releases opioid policy

The reveal comes days before hydrocodone products jump to a more restrictive access tier.

Advocates want FDA's Hamburg out

The reason: opioids.

Painkiller maker Acura gets NIH grant

The $300,000 grant will go towards an abuse-deterrent technology.

FDA wants more info on Acura pain drug

FDA wants more info on Acura pain drug

By

FDA feedback will influence a new clinical trial design, but the regulator's recent reaction was a bit of a surprise.

Daiichi increases efforts to break into opioid market

Daiichi increases efforts to break into opioid market

By

The drugmaker is collaborating with Charleston Laboratories in the development and commercialization of hydrocodone products. The deal means Daiichi Sankyo now has two pipeline opiates.

OPINION

Email Newsletters